NatWest Group (NYSE:NWG) Stock

NatWest Group

NatWest Group derives around 90% of its total income from the United Kingdom. The bank operates a retail, commercial, and private bank in the UK, offering clients lending and payment services as well as asset management services.

News

IPOs

AMBQ

Ambiq Micro IPO Opens For Trade At $38.80/Share; IPO Priced At $24/Share On 4M Shares

WIIM

VRNS

Varonis Systems shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance. Additionally, several firms raised their respective price targets on the stock.

A deeper push into collectibles <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45935585/gamestop-highlights-trading-cards-as-next-growth-segment-at-annual-meeting-not-bitcoin">and trading cards</a> continues for video game retailer GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) with the company's latest launch.
GME is currently moving to its 52-week bottom. <a href="https://www.benzinga.com/quote/GME" target="_blank" rel="noreferrer noopener">Track it now here.</a>
What Happened: GameStop is expanding its partnership with trading card grading company PSA, which is owned by Collectors Universe. The companies first <a href="https://www.benzinga.com/general/gaming/24/11/42047265/gamestop-adds-nat-turner-to-board-does-the-move-show-bigger-bet-on-trading-cards-grading">partnered in 2024 </a>and Collectors Universe CEO Nat Turner is a member of the GameStop board of directors.
Together, GameStop and PSA are <a href="https://powerpacks.gamestop.com/">launching </a>Power Packs, blind bags for adults 18 and up that contain one PSA-graded trading card in either the football or Pokémon category. The company plans on adding more categories in the future.
Currently available in a beta test, the blind bags come with the following levels and prices, as reported by <a href="https://www.cllct.com/sports-collectibles/sports-cards/gamestop-psa-partner-for-power-packs-trading-card-platform">cllct</a>:
<ul class="wp-block-list">
<li>Starter: $25</li>
<li>Silver: $50</li>
<li>Gold: $100</li>
<li>Platinum: $500</li>
<li>Diamond: $1,000</li>
</ul>
Inside each pack is one graded card and the purchaser has several options after opening the card digitally. They can keep the card, store it in the PSA Vault, pay a small fee to have it shipped to their house, or sell the card through an Instant Buyback, PSA Offers, or list the card on auction site eBay.
A transparent checklist for each price level is provided by the companies with chase cards valued at over $10,000 available in the higher level packs.
Most items opened will be valued at less than the purchase price based on the buyback prices and values provided by Card Ladder. This means that buying a $25 starter pack likely means getting a card worth $10 to $20 or with a buyback in that range, while some packs will have cards with buybacks of $100 or more. 
Repacks of trading cards, such as graded cards, have become popular with collectors due to the highly valued chase cards and the ability to strike it rich with a small buy-in and some luck.
The graded cards come with authenticity guaranteed and are 100% insured in the PSA Vault.
Consumers can sign up for the beta test on GameStop's website if they are 18 or older.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46448715/gamestop-ceo-is-not-scared-of-the-short-sellers-calls-it-un-american-to-bet-against-business-but-its-a-free-market">GameStop CEO Is &#8216;Not Scared Of The Short Sellers,&#8217; Calls It Un-American To Bet Against Business &#8216;But It&#8217;s A Free Market&#8217;</a>
Why It's Important: An initial partnership between GameStop and PSA in May 2024 saw the video game retailer buy and sell PSA-graded cards in stores. In October 2024, the companies expanded the partnership with GameStop, becoming an authorized partner for consumers to send in cards for grading with PSA.
In May 2025, GameStop announced it helped get over one million trading cards graded through the PSA program.
In the<a href="https://www.benzinga.com/markets/earnings/25/06/45872536/gamestop-q1-earnings-revenue-misses-despite-collectibles-growth-eps-beats-retailer-adds-4710-bitcoin"> most recent quarter</a>, GameStop reported Collectibles revenue of $211.5 million, outpacing the $175.6 million for the Software category. Of the three main categories of Hardware and Accessories, Software and Collectibles, the Collectibles segment was the only one with year-over-year revenue growth in the first quarter.
&#8220;We are focusing on trading cards as a natural extension of our existing business,&#8221; GameStop CEO Ryan Cohen said earlier this year. &#8220;The trading card market — whether it&#8217;s sports, Pokémon, or collectibles, is aligned with our heritage — it first our trading model, it appeals to our core customer base, and it&#8217;s deeply embedded in physical retail.&#8221;
Cohen said trading cards have &#8220;high margin potential&#8221; and are a &#8220;logical expansion.&#8221;
The strong trading card partnership and growth led to speculation that PSA could acquire GameStop. PSA denied the potential acquisition earlier this year.
GME Price Action: GameStop stock is up 0.91% to $22.76 versus a 52-week trading range of $18.73 to $35.81. GameStop stock is down 26% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/gaming/25/07/46455645/250000-for-a-stapler-gamestop-turns-blunder-into-big-charity-win">$250,000 For A Stapler? GameStop Turns Blunder Into Big Charity Win</a></li>
</ul>
Photos: Shutterstock

Gaming

Long Ideas

Sports

Trading Ideas

GameStop's $25 To $1,000 Pokemon Blind Bags Are Fueling A New Kind Of Collector FOMO

Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) reported its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46716697/tevas-innovative-portfolio-fuels-10th-consecutive-quarter-of-growth-in-q2-2025-increases-2025-reve" rel="noreferrer noopener">second-quarter 2025</a> financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy.
The company reported total revenue of $4.20 billion, falling short of analysts&#8217; expectations of $4.29 billion, according to <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>. This marks a flat year-over-year result in U.S. dollars, with a slight decline of 1% in local currency terms.
The revenue shortfall was primarily driven by weaker sales in Teva&#8217;s generic drug portfolio. Specifically, the decline in generic revenues from its International Markets segment, compounded by the divestment of its Japanese business and a drop in sales from Copaxone, weighed on overall results.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/07/46701886/generic-revlimid-fades-but-tevas-broader-generics-outlook-remains-strong" rel="noreferrer noopener">Generic Revlimid Fades, But Teva&#8217;s Broader Generics Outlook Remains Strong</a>
However, these declines were partially offset by strong sales growth from Teva&#8217;s innovative drug offerings, including Austedo, Uzedy, and Ajovy.
Sales of Copaxone, a key multiple sclerosis treatment, fell by 23%, contributing just $62 million in revenue for the quarter. On a more positive note, Teva&#8217;s innovative portfolio saw impressive growth.
Austedo, an FDA-approved treatment for tardive dyskinesia, saw a 19% increase in sales, reaching $498 million. Uzedy, used in the treatment of schizophrenia, more than doubled its sales, totaling $54 million. Similarly, Ajovy, a migraine treatment, reported a 31% year-over-year increase, bringing in $155 million.
Teva&#8217;s generic segment showed stable performance overall. Global generics revenues declined by 2% in local currency, excluding Japan&#8217;s business venture, while U.S. generics saw a 6% drop. In contrast, European generics grew by 1%, and revenues from the International Markets segment fell by 1%.
Teva also reported strong growth in its biosimilars segment. The company attributed this to the robust performance of both existing and newly launched biosimilars. Teva expects this segment to continue growing, with plans to launch two new biosimilars in the second half of 2025. The company is on track to double biosimilars revenues from 2024 to 2027, underscoring its commitment to expanding its portfolio in this rapidly growing sector.
For the second quarter, Teva reported adjusted earnings of 66 cents per share, surpassing <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">analyst estimates of 62 cents per share</a>. The adjusted gross profit margin for the quarter improved to 54.6%, compared to 52.9% in the same period last year, reflecting the favorable mix of higher-margin innovative products.
Teva&#8217;s President and CEO, Richard Francis, highlighted the company&#8217;s growing portfolio as a key driver of its financial performance. &#8220;Teva&#8217;s performance this quarter stands as a testament to the exceptional strength of our innovative portfolio, which remains the primary engine driving our revenue growth,&#8221; Francis said. &#8220;Our key innovative products delivered a 26% increase in local currency, demonstrating their impact on our financial trajectory and value to patients.&#8221;
During the earnings conference call, Francis stated that 70% of Teva&#8217;s generics business operates outside the U.S., while its most innovative business is U.S.-based. On the supply chain, Teva has no reliance on China and a very small presence in India.
Teva&#8217;s CFO Eli Kalif confirmed that U.S. tariffs are absorbed into their 2025 non-GAAP outlook, indicating proactive financial planning to manage these impacts.
<h2 class="wp-block-heading">Outlook</h2>
Teva Pharmaceutical narrowed its fiscal 2025 adjusted earnings guidance to a range of $2.50-$2.60 per share from $2.45-$2.65 per share, slightly below the consensus estimate of $2.53.
The company also reaffirmed its full-year sales guidance of $16.8 billion-$17.2 billion, slightly lower than the consensus expectation of $17.01 billion.
This outlook takes into account the potential impact of tariffs and trade uncertainties within the pharmaceutical sector.
Teva raised its sales outlook for several key products. The sales forecast for Austedo in 2025 was increased to between $2 billion and $2.05 billion, up from the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" rel="noreferrer noopener">prior estimate of $1.95-$2.05 billion</a>.
Similarly, the company now expects Ajovy sales to reach $630 million-$640 million, surpassing its earlier guidance of $600 million.
Sales expectations for Uzedy were also raised from approximately $160 million to a range of $190-$200 million. Teva also expects around $370 million in sales from Copaxone in 2025.
For its operating income and adjusted EBITDA, Teva reaffirmed its guidance range of $4.3 billion-$4.6 billion and $4.7 billion-$5 billion, respectively.
The company remains focused on executing its long-term strategy, which includes building a $5 billion innovative medicines franchise by 2030, supported by its key assets and <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45678673/teva-reaffirms-growth-strategy-eyes-5-billion-innovative-franchise-by-2030" rel="noreferrer noopener">promising late-stage pipeline</a>.
As the company continues its pivot toward innovative therapies, it remains to be seen how it will navigate potential headwinds, including tariff impacts and competition in both its generic and biosimilar segments.
Price Action: TEVA stock is trading higher by 2.36% to $16.94 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46725904/unitedhealth-prognosis-mixed-analysts-trim-targets-but-keep-faith-after-q2-miss" target="_blank" rel="noreferrer noopener">UnitedHealth Prognosis Mixed: Analysts Trim Targets But Keep Faith After Q2 Miss</a></li>
</ul>
Photo via Shutterstock

Earnings

Large Cap

Guidance

Health Care

Movers

General

TEVA

Teva Reaffirms 2025 Sales, Boosts Outlook For Austedo, Ajovy, Uzedy

CAKE

The Cheesecake Factory shares are trading higher after the company reported better-than-expected Q2 financial results. Also, several firms raised their respective price targets on the stock.

U.S. stocks inched higher midday Wednesday, as investors digested upbeat economic data while keeping an optimistic tone ahead of the Federal Reserve's policy decision and a wave of key tech earnings <a href="https://www.benzinga.com/markets/earnings/25/07/46693997/wall-street-earnings-preview-microsoft-apple-meta-amazon-mastercard-visa">due after the bell. </a>
<ul class="wp-block-list">
<li>The QQQ ETF is on track for a fourth consecutive monthly gain. <a href="https://www.benzinga.com/quote/QQQ">See the chart here.</a></li>
</ul>
The S&amp;P 500 rose 0.2%, the Nasdaq added 0.4%, and the Dow Jones hovered near the flatline. Small-cap stocks outperformed, with the Russell 2000 up 0.6%. 
Markets widely expect the Federal Reserve to keep rates steady at 4.25%-4.50%, but with two policymakers already showing preference for a cut, the decision could mark the most divided vote since 1993.
On the trade front, former President Donald Trump announced a new 25% tariff on Indian imports, set to take effect Aug. 1. 
Advance GDP data showed the U.S. economy grew at an annualized 3.0% in the second quarter of 2025, a sharp rebound from the previous quarter's 0.5% contraction and well above the 2.4% consensus, powered by strong consumer spending and a decline in imports. 
In the labor market, private payrolls rose by 104,000 in July, the strongest gain since March and a solid beat on the 75,000 forecast—reversing a contraction in June. 
Commodities were in focus as WTI crude extended its rally, surging 1.5% on the day to hit $70 a barrel, driven by geopolitical tensions following Trump's new 10-day ultimatum to Russia over peace talks with Ukraine. The three-day gain now totals over 8%.
Gold slipped 1% to $3,290 per ounce as the U.S. dollar strengthened on the back of robust economic data. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady around $118,000.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,257.27</td>
<td>0.6%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>23,396.45</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,384.59</td>
<td>0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,654.85</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:05 p.m. ET</figcaption></figure>
According to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) inched 0.1% higher to $584.81.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) flattened at $446.50.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.3% to $569.07.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 0.7% to $224.19.</li>
<li>The&nbsp;Utilities&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 1%; the&nbsp;Energy&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1%.</li>
</ul>
<h2 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h2>
<ul class="wp-block-list">
<li>Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) climbed 2.3%, poised to break a seven-day losing streak, after JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) announced a partnership with the crypto exchange that will allow Chase credit card holders to fund their Coinbase wallets and purchase cryptocurrencies. </li>
<li>Stocks moving on earnings reports included: 
<ul class="wp-block-list">
<li>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) up 0.8%</li>
<li>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) flat</li>
<li>Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) up 1.2%</li>
<li>Automatic Data Processing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) up 1.9%</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) up 0.7%</li>
<li>Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) up 2.0%</li>
<li>Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) down 7.8%</li>
<li>Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) down 6.0%</li>
<li>Illinois Tool Works Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) down 2.0%</li>
<li>Republic Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) down 5.0%</li>
<li>American Electric Power Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) up 3.8%</li>
<li>Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) up 1.6%</li>
<li>Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) down 5.5%</li>
<li>Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) up 7.2%</li>
<li>Entergy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) up 3.2%</li>
<li>Verisk Analytics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) down 4.8%</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) up 2.3%</li>
<li>WEC Energy Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) up 0.5%</li>
<li>Tradeweb Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>) up 4.9%</li>
<li>GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) down 4.9%</li>
<li>Arch Capital Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) down 1.0%</li>
<li>Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) down 8.8%</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) up 7.4%</li>
<li>Expand Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPN#NASDAQ">EXPN</a>) up 5.1%</li>
<li>Smurfit Westrock plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMUR#NYSE">SMUR</a>) down 2.1%</li>
<li>PPG Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) down 4.9%</li>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) up 3.6%</li>
<li>Essex Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) down 4.7%</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) up 21.2%</li>
<li>Fortive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) up 0.9%</li>
</ul>
</li>
</ul>
<h2 class="wp-block-heading">Stocks slated to report earnings after the close:</h2>
<ul class="wp-block-list">
<li>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</li>
<li>American Water Works Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>)</li>
<li>Antero Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>)</li>
<li>AvalonBay Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>)</li>
<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>)</li>
<li>C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>)</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)</li>
<li>Cognizant Technology Solutions Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>)</li>
<li>Confluent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>)</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)</li>
<li>eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>)</li>
<li>Equinix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>)</li>
<li>Everest Group, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>)</li>
<li>Extra Space Storage Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>)</li>
<li>F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>)</li>
<li>Fair Isaac Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>)</li>
<li>FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>)</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)</li>
<li>GFL Environmental Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>)</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>)</li>
<li>Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>)</li>
<li>Host Hotels &amp; Resorts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>)</li>
<li>Independence Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>)</li>
<li>Invitation Homes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>)</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>)</li>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>)</li>
<li>Mid-America Apartment Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>)</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>)</li>
<li>Prudential Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>)</li>
<li>PTC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>)</li>
<li>QUALCOMM Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>)</li>
<li>The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>)</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>)</li>
<li>UDR, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>)</li>
<li>Ventas, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>)</li>
<li>VICI Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>)</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</li>
</ul>
Now Read
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/07/46720292/us-gdp-q2-economy-us-trump-fed-interest-rates-dollar">US Economy Roars Back With 3% Growth, Handing Trump A Timely Victory </a></li>
</ul>
Image: Shutterstock

Equities

Macro Economic Events

Economics

Tech

ETFs

$BTC

ACGL

BKNG

CFLT

CHRW

COIN

CTSH

CVNA

SPDR Dow Jones Industrial Average ETF Trust

DXCM

EBAY

EQIX

EXPN

FFIV

FICO

GEHC

GRMN

HOLX

INVH

LRCX

MDLZ

MSFT

ODFL

QCOM

SBUX

SMUR

VICI

VRSK

Stocks Rise Ahead Of Fed Meeting, Oil Jumps To $70: What's Moving Markets Wednesday?

Stepan shares are trading lower after the company reported Q2 financial results and missed its adjusted EPS and revenue estimates.

Rumors

Ambiq Micro IPO Indicating $36-$36.25/Share On 450K Shares; IPO Priced At $24/Share On 4M Shares

PTHL

Pheton Holdings shares are trading lower following commentary on the stock from The Bear Cave.

<h3>Gainers</h3>
<ul>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNHP#NASDAQ">SLNHP</a>) shares increased by 23.6% to $4.29 during Wednesday's regular session. The company's market cap stands at $2.4 million. </li>
<li>Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) stock rose 19.63% to $108.33. The company's market cap stands at $14.5 billion. The company's, Q2 earnings came out yesterday. </li>
<li>Toyo Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOYO#NASDAQ">TOYO</a>) shares moved upwards by 17.84% to $5.02. The market value of their outstanding shares is at $198.4 million. </li>
<li>Blackbaud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLKB#NASDAQ">BLKB</a>) shares rose 14.31% to $73.73. The company's market cap stands at $3.1 billion. As per the news, the Q2 earnings report came out today. </li>
<li>Littelfuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFUS#NASDAQ">LFUS</a>) shares rose 13.23% to $267.0. The market value of their outstanding shares is at $5.8 billion. As per the press release, Q2 earnings came out today. </li>
<li>BeLive Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIV#NASDAQ">BLIV</a>) stock rose 12.87% to $2.28. The company's market cap stands at $21.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ScanTech AI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) shares decreased by 24.4% to $0.9 during Wednesday's regular session. The market value of their outstanding shares is at $24.6 million. </li>
<li>Global Engine Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLE#NASDAQ">GLE</a>) shares declined by 20.01% to $0.88. The company's market cap stands at $20.1 million. </li>
<li>Nvni Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) shares declined by 13.89% to $0.56. The company's market cap stands at $59.4 million. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) shares declined by 12.96% to $1.78. The company's market cap stands at $892.1 million. </li>
<li>Universal Security (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UUU#AMEX">UUU</a>) stock decreased by 9.18% to $3.23. The company's market cap stands at $8.2 million. As per the press release, Q4 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLIV

BLKB

LFUS

NVNI

Next Technology Holding Inc. - Ordinary Shares

NXTT

SLNHP

STAI

TOYO

11 Information Technology Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Super X AI Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPX#NASDAQ">SUPX</a>) shares rose 47.4% to $23.75 during Wednesday's regular session. The market value of their outstanding shares is at $357.3 million. </li>
<li>Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) shares increased by 25.89% to $365.49. The company's market cap stands at $8.3 billion. The company's, Q2 earnings came out today. </li>
<li>Rocky Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) stock rose 23.71% to $28.43. The market value of their outstanding shares is at $171.4 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Premium Catering (Hldgs) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PC#NASDAQ">PC</a>) stock rose 18.88% to $7.49. The market value of their outstanding shares is at $11.1 million. </li>
<li>ATA Creativity Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) shares rose 18.38% to $1.51. The market value of their outstanding shares is at $40.1 million. </li>
<li>Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) stock rose 18.28% to $7.31. The market value of their outstanding shares is at $2.4 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) stock fell 24.6% to $0.54 during Wednesday's regular session. The market value of their outstanding shares is at $14.3 million. </li>
<li>Monro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) shares fell 18.76% to $13.26. The company's market cap stands at $489.0 million. As per the press release, Q1 earnings came out today. </li>
<li>Lazydays Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) stock fell 16.36% to $5.32. The company's market cap stands at $23.3 million. </li>
<li>Camping World Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWH#NYSE">CWH</a>) stock declined by 12.87% to $15.37. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) shares decreased by 12.62% to $0.18. The market value of their outstanding shares is at $9.8 million. </li>
<li>Netclass Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) shares declined by 11.78% to $2.04. The market value of their outstanding shares is at $41.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AACG

ECDA

FTEL

GORV

MNRO

NTCL

PTON

RCKY

SUPX

WING

12 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock rose 100.5% to $7.52 during Wednesday's regular session. The company's market cap stands at $291.7 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock increased by 35.38% to $9.68. The company's market cap stands at $22.4 million. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock rose 28.1% to $7.43. The market value of their outstanding shares is at $18.9 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares rose 24.1% to $8.37. The market value of their outstanding shares is at $308.0 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock moved upwards by 23.52% to $2.1. The market value of their outstanding shares is at $137.5 million. </li>
<li>Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) shares rose 20.96% to $15.52. The company's market cap stands at $1.3 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) stock declined by 73.4% to $0.38 during Wednesday's regular session. The company's market cap stands at $23.9 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) stock decreased by 43.49% to $0.93. The market value of their outstanding shares is at $23.9 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock fell 33.08% to $0.03. The market value of their outstanding shares is at $20.7 million. </li>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) shares fell 25.08% to $2.48. The company's market cap stands at $220.2 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) stock declined by 24.29% to $8.45. The market value of their outstanding shares is at $160.0 million. As per the press release, Q2 earnings came out today. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock decreased by 23.97% to $0.76. The market value of their outstanding shares is at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANIK

BHVN

CAPR

CRDF

HCTI

IMAB

PIII

REPL

SLRX

VYNE

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) shares moved upwards by 39.9% to $6.24 during Wednesday's regular session. The company's market cap stands at $8.0 million. </li>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) shares moved upwards by 38.88% to $0.2. The company's market cap stands at $2.6 million. </li>
<li>Tigo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>) stock moved upwards by 33.49% to $1.64. The market value of their outstanding shares is at $76.2 million. The company's, Q2 earnings came out yesterday. </li>
<li>Quhuo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>) stock rose 26.44% to $0.13. The market value of their outstanding shares is at $9.1 million. </li>
<li>FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) stock moved upwards by 23.33% to $140.77. The company's market cap stands at $11.7 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Global Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIC#NYSE">GIC</a>) stock increased by 23.16% to $33.39. The company's market cap stands at $1.0 billion. The company's, Q2 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SOS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOS#NYSE">SOS</a>) stock fell 55.4% to $2.68 during Wednesday's regular session. The company's market cap stands at $18.2 million. </li>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares declined by 27.86% to $0.28. The market value of their outstanding shares is at $3.5 million. </li>
<li>Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) shares decreased by 16.57% to $1.49. The company's market cap stands at $3.4 million. </li>
<li>Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) shares decreased by 15.2% to $172.91. The market value of their outstanding shares is at $7.1 billion. The company's, Q2 earnings came out yesterday. </li>
<li>Columbus McKinnon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCO#NASDAQ">CMCO</a>) stock decreased by 13.88% to $14.52. The market value of their outstanding shares is at $482.7 million. As per the news, the Q1 earnings report came out today. </li>
<li>Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) shares decreased by 12.68% to $5.07. The company's market cap stands at $303.6 million. As per the press release, Q2 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGLC

CMCO

DFLI

FTAI

QUAD

SOAR

TYGO

12 Industrials Stocks Moving In Wednesday's Intraday Session

Montrose Environmental Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEG#NYSE">MEG</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Montrose Environmental Gr to report an earnings per share (EPS) of $-0.09.
Investors in Montrose Environmental Gr are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.02, which was followed by a 32.63% increase in the share price the next day.
Here's a look at Montrose Environmental Gr's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.09</td>
<td>0.31</td>
<td>0.35</td>
<td>-0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.07</td>
<td>0.29</td>
<td>0.41</td>
<td>0.20</td>
</tr>
<tr>
<td>Price Change %</td>
<td>18.0%</td>
<td>33.0%</td>
<td>-3.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753894973_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Montrose Environmental Gr were trading at $22.39 as of July 29. Over the last 52-week period, shares are down 25.24%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analysts' Perspectives on Montrose Environmental Gr</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Montrose Environmental Gr.
A total of 1 analyst ratings have been received for Montrose Environmental Gr, with the consensus rating being Buy. The average one-year price target stands at $30.0, suggesting a potential 33.99% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of CECO Environmental, Mobile Infrastructure and BrightView Hldgs, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for CECO Environmental, with an average 1-year price target of $49.5, suggesting a potential 121.08% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Mobile Infrastructure, with an average 1-year price target of $6.5, suggesting a potential 70.97% downside.</li>
<li>Analysts currently favor an Buy trajectory for BrightView Hldgs, with an average 1-year price target of $19.5, suggesting a potential 12.91% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for CECO Environmental, Mobile Infrastructure and BrightView Hldgs are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Montrose Environmental Gr</td>
<td>Buy</td>
<td>14.49%</td>
<td>$69.43M</td>
<td>-4.97%</td>
</tr>
<tr>
<td>CECO Environmental</td>
<td>Buy</td>
<td>39.87%</td>
<td>$62.16M</td>
<td>13.49%</td>
</tr>
<tr>
<td>Mobile Infrastructure</td>
<td>Outperform</td>
<td>-6.71%</td>
<td>$4.46M</td>
<td>-2.49%</td>
</tr>
<tr>
<td>BrightView Hldgs</td>
<td>Buy</td>
<td>-1.53%</td>
<td>$147.50M</td>
<td>-0.19%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Montrose Environmental Gr ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is at the top for Return on Equity.
<h3>Delving into Montrose Environmental Gr's Background</h3>
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, remove contaminant or create biogas. United States Contributes the majority of geographic revenue.
<h3>Financial Milestones: Montrose Environmental Gr's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Montrose Environmental Gr's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 14.49%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Montrose Environmental Gr's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -12.43%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Montrose Environmental Gr's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -4.97%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.23%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Montrose Environmental Gr's debt-to-equity ratio is below the industry average at 0.68, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/MEG/earnings">To track all earnings releases for Montrose Environmental Gr visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Examining the Future: Montrose Environmental Gr's Earnings Outlook

Matson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATX#NYSE">MATX</a>) will release its quarterly earnings report on Thursday, 2025-07-31. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Matson to report an earnings per share (EPS) of $2.24.
The announcement from Matson is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.09, which was followed by a 15.41% drop in the share price the next day.
Here's a look at Matson's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.27</td>
<td>3.2</td>
<td>4.74</td>
<td>3</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.18</td>
<td>3.8</td>
<td>5.89</td>
<td>3.31</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-15.0%</td>
<td>2.0%</td>
<td>16.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753894962_0.png" alt="eps graph" />
<h3>Market Performance of Matson's Stock</h3>
Shares of Matson were trading at $107.44 as of July 29. Over the last 52-week period, shares are down 16.11%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MATX/earnings">To track all earnings releases for Matson visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MATX

A Preview Of Matson's Earnings

Let's get into it… today's one of those days where every hour has a headline. But first, yesterday morning started with a batch of earnings from fintech and healthcare. And then of course we're heading straight into a firestorm after the bell, today, with $6.5 trillion in market cap set to report. Oh, and the Fed meets today. No pressure.
<h3 class="wp-block-heading">Fintech and Healthcare Check-In</h3>
SoFi Technologies (SOFI) delivered its 17th straight revenue beat, coming in at $498M vs. $487M estimates. Personal loan originations are still strong, but commentary hinted at tighter lending standards ahead.
PayPal (PYPL) is in slow-motion turnaround mode. Total Payment Volume (TPV) was $404B vs. $402B expected, with active accounts roughly flat. Venmo growth was stagnant, and while cost cuts helped margins, investors are still waiting for a spark.
Novo Nordisk (NVO) slid after revising guidance lower… pressure in the U.S. obesity drug channel is real, even for a GLP-1 giant. Ozempic and Wegovy sales are still growing, but at a more measured pace. New CEO stepping in as they recalibrate the next phase of growth.
 UnitedHealth (UNH) dropped like a rock after earnings, despite relatively in-line numbers. The issue? A weaker outlook for FY2025, rising medical costs, and ongoing Medicare probe headlines. Investors clearly want more reassurance from management… and they didn't get it.
<h3 class="wp-block-heading">Eyes on the Fed: Will They or Won't They?</h3>
The FOMC meeting wraps up today (Wednesday), and no one's expecting a miracle. There's only a&nbsp;2.6% chance&nbsp;of a rate cut… essentially none. But every word from Powell matters, especially with inflation showing mixed signals and GDP forecasts cooling.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.

Opinion

Federal Reserve

Only A 2.6% Chance Of A Fed Rate Cut; Fintech, Healthcare Earnings In Focus

Idacorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDA#NYSE">IDA</a>) is preparing to release its quarterly earnings on Thursday, 2025-07-31. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Idacorp to report an earnings per share (EPS) of $1.75.
Anticipation surrounds Idacorp's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.05 in the last quarter, leading to a 0.33% increase in the share price on the following day.
Here's a look at Idacorp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.05</td>
<td>0.63</td>
<td>2.18</td>
<td>1.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.10</td>
<td>0.70</td>
<td>2.12</td>
<td>1.71</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>1.0%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753894953_0.png" alt="eps graph" />
<h3>Idacorp Share Price Analysis</h3>
Shares of Idacorp were trading at $122.58 as of July 29. Over the last 52-week period, shares are up 20.28%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on Idacorp</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Idacorp.
Idacorp has received a total of 5 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $123.8, the consensus suggests a potential 1.0% upside.
<h3>Comparing Ratings with Competitors</h3>
The analysis below examines the analyst ratings and average 1-year price targets of and TXNM Energy, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for TXNM Energy, with an average 1-year price target of $60.5, suggesting a potential 50.64% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
In the peer analysis summary, key metrics for and TXNM Energy are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Idacorp</td>
<td>Neutral</td>
<td>-3.67%</td>
<td>$55.56M</td>
<td>1.79%</td>
</tr>
<tr>
<td>TXNM Energy</td>
<td>Neutral</td>
<td>10.51%</td>
<td>$289.06M</td>
<td>0.35%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Idacorp ranks higher than its peer in terms of revenue growth, with a negative growth rate compared to a positive growth rate. It also outperforms in gross profit margin. However, it has a lower return on equity compared to its peer.
<h3>Unveiling the Story Behind Idacorp</h3>
Idacorp Inc is a holding company that, through its subsidiaries, acts as an electric utility engaged in the generation, transmission, distribution, sale, and purchase of electric energy and capacity. The companys only reportable segment is utility operations. The utility operations segment's primary source of revenue is the regulated operations of Idaho Power. The company serves commercial and industrial customers, which involved in food processing, electronics and general manufacturing, agriculture, health care, government, and education.
<h3>Idacorp: Delving into Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Idacorp's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -3.67%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Utilities sector.
Net Margin: Idacorp's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.79% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Idacorp's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.79%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Idacorp's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.63%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Idacorp's debt-to-equity ratio is below the industry average at 1.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/IDA/earnings">To track all earnings releases for Idacorp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Idacorp's Earnings Potential

Healthcare Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) will release its quarterly earnings report on Thursday, 2025-07-31. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Healthcare Realty Trust to report an earnings per share (EPS) of $0.11.
The announcement from Healthcare Realty Trust is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.00, leading to a 4.28% drop in the share price on the subsequent day.
Here's a look at Healthcare Realty Trust's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.39</td>
<td>0.39</td>
<td>0.38</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.39</td>
<td>0.40</td>
<td>0.39</td>
<td>0.38</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<h3>Market Performance of Healthcare Realty Trust's Stock</h3>
Shares of Healthcare Realty Trust were trading at $15.84 as of July 29. Over the last 52-week period, shares are down 9.4%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on Healthcare Realty Trust</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Healthcare Realty Trust.
Analysts have provided Healthcare Realty Trust with 3 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $16.0, suggesting a potential 1.01% upside.
<h3>Peer Ratings Overview</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of CareTrust REIT, American Healthcare REIT and Sabra Health Care REIT, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for CareTrust REIT, with an average 1-year price target of $32.0, suggesting a potential 102.02% upside.</li>
<li>Analysts currently favor an Outperform trajectory for American Healthcare REIT, with an average 1-year price target of $41.2, suggesting a potential 160.1% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Sabra Health Care REIT, with an average 1-year price target of $19.5, suggesting a potential 23.11% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for CareTrust REIT, American Healthcare REIT and Sabra Health Care REIT, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare Realty Trust</td>
<td>Neutral</td>
<td>-8.52%</td>
<td>$184.01M</td>
<td>-0.88%</td>
</tr>
<tr>
<td>CareTrust REIT</td>
<td>Outperform</td>
<td>33.91%</td>
<td>$69.48M</td>
<td>2.25%</td>
</tr>
<tr>
<td>American Healthcare REIT</td>
<td>Outperform</td>
<td>8.22%</td>
<td>$108.18M</td>
<td>-0.30%</td>
</tr>
<tr>
<td>Sabra Health Care REIT</td>
<td>Neutral</td>
<td>10.07%</td>
<td>$123.61M</td>
<td>1.48%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Healthcare Realty Trust ranks at the bottom for Revenue Growth and Gross Profit, with negative growth and profit margin. It also has the lowest Return on Equity among its peers. Overall, the company's performance is weaker compared to its peers in the healthcare real estate sector.
<h3>Unveiling the Story Behind Healthcare Realty Trust</h3>
Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.
<h3>Financial Milestones: Healthcare Realty Trust's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: Healthcare Realty Trust's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -8.52%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Healthcare Realty Trust's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -15.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Healthcare Realty Trust's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.88%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Healthcare Realty Trust's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.43%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.99.
<a href="https://www.benzinga.com/quote/HR/earnings">To track all earnings releases for Healthcare Realty Trust visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Healthcare Realty Trust's Earnings

Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) is preparing to release its quarterly earnings on Thursday, 2025-07-31. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Boot Barn Holdings to report an earnings per share (EPS) of $1.53.
Investors in Boot Barn Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.03, which was followed by a 16.66% increase in the share price the next day.
Here's a look at Boot Barn Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2025</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.25</td>
<td>2.38</td>
<td>0.95</td>
<td>1.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.22</td>
<td>2.43</td>
<td>0.95</td>
<td>1.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>17.0%</td>
<td>-8.0%</td>
<td>-20.0%</td>
<td>14.000000000000002%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753894927_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Boot Barn Holdings were trading at $175.11 as of July 29. Over the last 52-week period, shares are up 40.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on Boot Barn Holdings</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Boot Barn Holdings.
Analysts have provided Boot Barn Holdings with 12 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $189.08, suggesting a potential 7.98% upside.
<h3>Analyzing Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Abercrombie &amp; Fitch, Urban Outfitters and Gap, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Abercrombie &amp; Fitch, with an average 1-year price target of $117.62, suggesting a potential 32.83% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Urban Outfitters, with an average 1-year price target of $69.33, suggesting a potential 60.41% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Gap, with an average 1-year price target of $28.36, suggesting a potential 83.8% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Abercrombie &amp; Fitch, Urban Outfitters and Gap, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boot Barn Holdings</td>
<td>Outperform</td>
<td>16.81%</td>
<td>$168.56M</td>
<td>3.38%</td>
</tr>
<tr>
<td>Abercrombie &amp; Fitch</td>
<td>Outperform</td>
<td>7.50%</td>
<td>$680.18M</td>
<td>6.37%</td>
</tr>
<tr>
<td>Urban Outfitters</td>
<td>Neutral</td>
<td>10.72%</td>
<td>$489.06M</td>
<td>4.42%</td>
</tr>
<tr>
<td>Gap</td>
<td>Outperform</td>
<td>2.21%</td>
<td>$1.45B</td>
<td>5.86%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Boot Barn Holdings ranks highest in Revenue Growth among its peers. It also has the highest Gross Profit margin. However, it has the lowest Return on Equity. Overall, Boot Barn Holdings is positioned at the top in terms of Revenue Growth and Gross Profit, but falls behind in Return on Equity compared to its peers.
<h3>All You Need to Know About Boot Barn Holdings</h3>
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
<h3>A Deep Dive into Boot Barn Holdings's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Boot Barn Holdings showcased positive performance, achieving a revenue growth rate of 16.81% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Boot Barn Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Boot Barn Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of 3.38%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Boot Barn Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.86% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Boot Barn Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.5.
<a href="https://www.benzinga.com/quote/BOOT/earnings">To track all earnings releases for Boot Barn Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BOOT

Insights into Boot Barn Holdings's Upcoming Earnings

Autohome (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATHM#NYSE">ATHM</a>) will release its quarterly earnings report on Thursday, 2025-07-31. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Autohome to report an earnings per share (EPS) of $0.47.
The announcement from Autohome is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.03, leading to a 1.02% drop in the share price on the subsequent day.
Here's a look at Autohome's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.46</td>
<td>0.51</td>
<td>0.52</td>
<td>0.56</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.49</td>
<td>0.55</td>
<td>0.58</td>
<td>0.65</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>3.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753894916_0.png" alt="eps graph" />
<h3>Autohome Share Price Analysis</h3>
Shares of Autohome were trading at $27.55 as of July 29. Over the last 52-week period, shares are up 18.07%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ATHM/earnings">To track all earnings releases for Autohome visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATHM

Insights Ahead: Autohome's Quarterly Earnings

Bank of America

Banco Bradesco Sa American Depositary Shares

Bank Bradesco

Banco Bradesco Sa American Depositary Shares (each representing one Common Share)

Banco Bilbao Vizcaya Argentaria S.A. Common Stock

BBVA

Barclays

Banco Santander Brasil SA American Depositary Shares, each representing one unit

Banco Santander

Citigroup

First Citizens BancShares, Inc. - Class A Common Stock

First Citizens BancShares

Fifth Third Bancorp

HDFC Bank

HSBC Holdings

ICICI Bank

ING Groep

Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)

Itau Unibanco Holding

JPMorgan Chase

KB Financial Group

Lloyds Banking Group Plc American Depositary Shares

Lloyds Banking Group

Mizuho Financial Group, Inc. Sponosred ADR (Japan)

Mizuho Financial Gr

Mitsubishi UFJ Financial Group, Inc. Common Stock

Mitsubishi UFJ Finl Gr

Nu Holdings

NatWest Group plc American Depositary Shares, (each representing two (2) Ordinary Shares)

PNC Financial Services Group, Inc. (The) Common Stock

PNC Financial Services Gr

Banco Santander, S.A. Sponsored ADR (Spain)

Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)

Sumitomo Mitsui Finl Gr

U.S. Bancorp

Wells Fargo

Comments

NatWest Group

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL